More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.80B
EPS
0.3
P/E ratio
265.7
Price to sales
4.98
Dividend yield
--
Beta
1.231621
Previous close
$55.31
Today's open
$55.32
Day's range
$53.88 - $55.98
52 week range
$25.36 - $66.02
show more
CEO
Michael H. Carrel
Employees
1350
Headquarters
Mason, OH
Exchange
NASDAQ Global Market
Shares outstanding
50922283
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
AtriCure to Participate in the Piper Sandler 38th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 38th Annual Healthcare Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, December 1, 2026, at 11:30 a.m. Eastern Standard Time. Interested partie.
Business Wire • Nov 17, 2026

AtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference Transcript
AtriCure, Inc. ( ATRC ) 2026 UBS Global Healthcare Conference November 9, 2026 11:00 AM EST Company Participants Angela Wirick - Chief Financial Officer Conference Call Participants Patrick Andrew Wood - UBS Investment Bank, Research Division Presentation Patrick Andrew Wood UBS Investment Bank, Research Division Welcome. Thanks, everyone.
Seeking Alpha • Nov 9, 2026

AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy
AtriCure is shifting from targeting AF patients to all open-heart surgery patients, aiming for broader adoption as a preventive standard of care. Upcoming catalysts include the STS quality metric rollout in 2027, BoxX-NoAF trial results in spring 2027, and the LeAAPS trial, all supporting institutional adoption. ATRC achieved GAAP profitability, with Q3 revenue up 15% year-over-year and adjusted EBITDA up 50.6%, signaling strong operating leverage and healthy cash generation.
Seeking Alpha • Nov 8, 2026

AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results
AtriCure, Inc. (NASDAQ:ATRC) on Tuesday posted upbeat results for the third quarter.
Benzinga • Nov 4, 2026

AtriCure, Inc. (ATRC) Q3 2026 Earnings Call Transcript
AtriCure, Inc. ( ATRC ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Participants Marissa Bych - Gilmartin Group LLC Matthew O'Brien - Piper Sandler & Co., Research Division John Young - Canaccord Genuity Corp., Research Division Marie Thibault - BTIG, LLC, Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Joseph Conway - Needham & Company, LLC, Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to AtriCure's Third Quarter 2026 Earnings Conference Call.
Seeking Alpha • Nov 4, 2026

What AtriCure (ATRC) Said on Its Q3 Earnings Call
AtriCure NASDAQ: ATRC reported third-quarter 2026 revenue of $154.5 million, up 15% from a year earlier, as growth in its U.S. open ablation, appendage management and pain management businesses helped lift profitability.
MarketBeat • Nov 4, 2026

AtriCure Reports Third Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2026 financial results. “Our third quarter results demonstrate the strength of our broad portfolio and our team's disciplined execution,” said Michael Carrel, President and Chief Executive Officer. “Adoption of our innovative technologies is dr.
Business Wire • Nov 3, 2026

Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 3, 2026

AtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates
AtriCure (ATRC) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.01 per share a year ago.
Zacks Investment Research • Nov 3, 2026

Riverwater Small Cap Strategy Q3 2026 Portfolio Update
During the third quarter of 2026, the Small Cap strategy slightly underperformed its benchmark, the Russell 2000 Index, in a period in which small cap stocks broadly declined. Top contributors include AtriCure and Red Violet; top detractors include Kodiak Gas Services and PDF Solutions. We initiated a position in IRadimed at the start of the quarter, replacing Talkspace after it was acquired.
Seeking Alpha • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell AtriCure Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.